Hepatitis C Virus and Treatment at Tobruk Liver Disease Center

Mahboba Aldareh; Sana I. Souliman

doi:10.64516/atwq1w12

Authors

Mahboba Aldareh Faculty of Medical Technology, Tobruk University, Tobruk, Libya Author
Sana I. Souliman Faculty of Medical Technology, Tobruk University, Tobruk, Libya Author

DOI:

https://doi.org/10.64516/atwq1w12

Keywords:

liver diseas, hepatitis C, treatment hepatitis C, Tobruk liver disease centre.

Abstract

A liver is vital organ in human body. It’s not just responsible for nutrient and filters of the blood but also for fights infections. Because of this function, any inflammatory condition of the liver causes hepatitis and it’s commonly caused by a viral infection. Globally, viral hepatitis types are hepatitis A, hepatitis B, hepatitis C, hepatitis D& hepatitis E. A substantial health threat to humans and causes approximately 700,000 deaths each year worldwide is recorded by hepatitis C virus. However, 30 years after the discovery of this virus in 1989, nearly perfect antiviral drugs that can clear up to 95% of this virus have been developed. This study investigated which type of hepatitis (A,B&C) was common between patients and also the most male & female patients who HCV infection at Tobruk liver centre in Tobruk city, in addation, the common drug that used in Liver disease centre in Tobruk. The data was collected from Tobruk liver disease centre from January to March. It shows that hepatitis C was common among patients. Females are most HCV infected than male as 22 to 17 respectively. The common drug used for HCV treatment in Tobruk liver disease centre is Sofosbuvir - Ledipasvir 400/90mg tablet (Harmony).

References

1. Baden R, Rockstroh JK, Buti M. Natural history and management of hepatitis C: does sex play a role? J Infect Dis. 2014;209(Suppl 3):S81–S85.

2. Butterfield MI, Bosworth HB, Meador KG, Stechuchak KM, Essock SM, Osher FC, et al. Gender differences in hepatitis C infection and risks among persons with severe mental illness. Psychiatr Serv. 2003;54(6):848–53. https://doi.org/10.1176/appi.ps.54.6.848

3. Czelusta A, Yen-Moore A, Van der Straten M, Carrasco D, Tyring SK. An overview of sexually transmitted diseases. Part III. Sexually transmitted diseases in HIV-infected patients. J Am Acad Dermatol. 2000;43(3):409–36.

4. Hofstraat SHI, Falla AM, Duffell EF, Hahne SJM, Amato-Gauci AJ, Veldhuijzen IK, Tavoschi L. Current prevalence of chronic hepatitis B and C virus infection in the general population, blood donors and pregnant women in the EU/EEA: a systematic review. Epidemiol Infect. 2017;145(14):2873–85.

5. Gritsenko D, Hughes G. Ledipasvir/Sofosbuvir (Harvoni): improving options for hepatitis C virus infection. P T. 2015;40(4):256.

6. Mehraj V, Routy JP. Tryptophan catabolism in chronic viral infections: handling uninvited guests. Int J Tryptophan Res. 2015;8:IJTR-S26862.

7. Musleh MM, Alajrami E, Khalil AJ, Abu-Nasser BS, Barhoom AM, Naser SA. Predicting Liver Patients using Artificial Neural Network. Int J Acad Inf Syst Res. 2019;3(10).

8. Novo-Veleiro I, Alvela-Suárez L, Chamorro AJ, González-Sarmiento R, Laso FJ, Marcos M. Alcoholic liver disease and hepatitis C virus infection. World J Gastroenterol. 2016;22(4):1411.

9. Niu Z, Zhang P, Tong Y. Age and gender distribution of Hepatitis C virus prevalence and genotypes of individuals of physical examination in WuHan, Central China. SpringerPlus. 2016;5(1):1557. https://doi.org/10.1186/s40064-016-3224-z

10. World Health Organization. Hepatitis C. 2021. Available from: https://www.who.int/news-room/fact-sheets/detail/hepatitis-c